STN1013800
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for STN1013800, covering 2025-03-20 to 2025-03-20. Get the full timeline:
Most recent: Clinical Trial Update: LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis. [Phase 3]